Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure
Abstract Rational use of phosphodiesterase inhibitors represents an ongoing controversy in contemporary pharmacotherapy for heart failure. In randomized clinical trials, phosphodiesterase inhibitors increased cardiac output at the expense of worsening the rates of sudden cardiac death and cardiovascular mortality. Preliminary findings from ongoing clinical and preclinical investigations of phosphodiesterase activity suggest that combined use of phosphodiesterase inhibitors with beta-adrenergic antagonists may prevent these adverse outcomes. Compartmentation of cyclic adenosine 3',5'-monophosphate signaling may prove critical in determining myocardial response to combination therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2008 |
|---|---|
| Erschienen: |
2008 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Pharmacotherapy - 28(2008), 12 vom: 15. Dez., Seite 1523-30 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Van Tassell, Benjamin W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenergic beta-Antagonists |
|---|
| Anmerkungen: |
Date Completed 23.02.2009 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1592/phco.28.12.1523 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM184645417 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM184645417 | ||
| 003 | DE-627 | ||
| 005 | 20231223171037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2008 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1592/phco.28.12.1523 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0616.xml |
| 035 | |a (DE-627)NLM184645417 | ||
| 035 | |a (NLM)19025433 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Van Tassell, Benjamin W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure |
| 264 | 1 | |c 2008 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2009 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Abstract Rational use of phosphodiesterase inhibitors represents an ongoing controversy in contemporary pharmacotherapy for heart failure. In randomized clinical trials, phosphodiesterase inhibitors increased cardiac output at the expense of worsening the rates of sudden cardiac death and cardiovascular mortality. Preliminary findings from ongoing clinical and preclinical investigations of phosphodiesterase activity suggest that combined use of phosphodiesterase inhibitors with beta-adrenergic antagonists may prevent these adverse outcomes. Compartmentation of cyclic adenosine 3',5'-monophosphate signaling may prove critical in determining myocardial response to combination therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 650 | 7 | |a Phosphodiesterase Inhibitors |2 NLM | |
| 650 | 7 | |a Cyclic AMP |2 NLM | |
| 650 | 7 | |a E0399OZS9N |2 NLM | |
| 700 | 1 | |a Radwanski, Przemyslaw |e verfasserin |4 aut | |
| 700 | 1 | |a Movsesian, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Munger, Mark A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacotherapy |d 1983 |g 28(2008), 12 vom: 15. Dez., Seite 1523-30 |w (DE-627)NLM012960926 |x 1875-9114 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2008 |g number:12 |g day:15 |g month:12 |g pages:1523-30 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1592/phco.28.12.1523 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2008 |e 12 |b 15 |c 12 |h 1523-30 | ||